

10 July 2025

**Physiomics plc
("Physiomics" or the "Company")**

Physiomics Implements Personalised Dosing Software onto the DoseMeRx Platform and expands partnership with DoseMe

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the implementation of the Company's personalised dosing software onto the DoseMeRx platform and the expansion of its partnership with DoseMe to support the development of new dosing solutions.

Following several iterations of software deployment, evaluation and debugging, the Company has successfully implemented its dosing software onto DoseMe's latest platform. This now allows the tool to be made available to clinicians and health care providers on a research-only basis allowing for important human factor evaluation and additional validation data to be generated.

In addition, Physiomics and DoseMe have agreed non-binding Heads of Terms with the intention of expanding their partnership beyond the Company's current personalised dosing software.

Background

The Company's personalised dosing software has been developed primarily with grant funding from UK bodies, including £68,000 from Innovate UK (March 2018), £150,000 from the National Institute for Health and Care Research to fund the PARTNER study (March 2020), and most recently £137,376 from Innovate UK and The Office for Life Sciences to fund the PREDICT-ONC study (November 2023).

Initially focused on supporting dosing decisions for cancer chemotherapies (such as docetaxel), a second use-case for the dosing software was identified following completion of the PARTNER study in 2023. Since chemotherapy often causes reduction of white cell counts (neutropenia), patients undergoing treatment have an elevated risk of infection and hospitalisation. In attempt to mitigate such risks, clinicians often prescribe an expensive biologic treatment called, Granulocyte-colony stimulating factor (G-CSF) which helps increase white blood cell counts. Optimising the dosing of G-CSF for each patient is crucial to minimise side-effects attributed to the therapy, whilst keeping treatment costs down. Through the PREDICT-ONC trial, the Company aims to generate additional data to further refine and validate the dosing software for use with G-CSF and docetaxel.

DoseMe

DoseMe is a US based leading provider of model-informed precision dosing (MIPD) software, providing clinicians worldwide 'easy-to-use', decision-support tools to guide personalized dosing. In July 2024, DoseMe announced a major update of its DoseMeRx platform, creating a new user experience with added functionality. The platform is used by clinicians and practitioners worldwide, supporting dosing decisions for the treatment of a wide variety of diseases. As the largest Bayesian dosing platform in the US, with deployment across Europe, UK and further afield, the DoseMeRx platform provides Physiomics an effective route to initially deploy, but then eventually commercialise their Personalised Dosing Software. Furthermore, due to complimentary capabilities across the DoseMe and Physiomics businesses, both parties have identified the opportunities to collaborate on the development of new dosing software tools beyond GCSF and docetaxel.

The partnership builds on each party's core strengths, combining Physiomics' oncology and modelling expertise with DoseMe's experience in delivering dosing tools at scale, within clinical workflows.

Expansion of collaboration

Physiomics and DoseMe have recently signed non-binding Heads of Terms with the intention of expanding their partnership beyond the Company's current personalised dosing software. This agreement defines terms across four areas of collaboration:

- development and commercialisation of novel dosing software tools originating from Physiomics;
- development and commercialisation of novel dosing software tools originating from DoseMe or its clients;
- provision of consultancy services by the Company to DoseMe; and
- co-development of clinical trial dosing software in support of biopharmaceutical clients.

The two parties are actively working to identify potential projects falling under these umbrella categories and further announcements on this will be made when appropriate.

Next steps

The implementation of the Company's personalised dosing software onto the DoseMeRx platform is an important step towards its eventual commercialisation. As next steps, the Company is focused on two main areas:

1. **Refinement and Validation:** The Innovate funded clinical trial that is projected to complete early next year is starting to generate the data needed to further refine and validate the personalised dosing software. In parallel, the Company is also exploring other sources of data, either in the public domain or available at clinical sites, to accelerate this process.
2. **Human Factor Evaluation:** In addition to refinement and validation of the personalised dosing software, the Company aims to identify clinicians and health practitioners to evaluate the software from a user experience perspective. These insights will help ensure the software can be used effectively in a clinical setting.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are very excited to announce our expanded partnership with DoseMe and the implementation of our Personalised Dosing Software onto their newly launched DoseMeRx platform. This not only marks a positive step towards the eventual commercialisation of our current Personalised Dosing Software, but also our ambition to apply our extensive modelling expertise into the development of new dosing software, either in oncology or beyond."

Dr Sharmeen Roy, PharmD, BCPS, Chief Strategy and Science Office of DoseMe, Commented:

"Embedding Physiomics' oncology models into DoseMeRx aligns with our focus on advancing transitional precision dosing. This collaboration expands our oncology strategy and supports the broader clinical adoption of model-informed approaches."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO
+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

About DoseMe

DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit <https://doseme-rx.com/success-stories>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSSDFWUEISEEW